ALT
$11.21
Altimmune
($.18)
(1.58%)
ALT
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.92)
Revenue:  $0.75 Mil
Wednesday
Nov 11
Before the open
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALT reports earnings?
Beat
Meet
Miss

Where is ALT's stock price going from here?
Up
Flat
Down
Stock chart of ALT
Analysts
Summary of analysts' recommendations for ALT
Score
Grade
Pivots
Resistance
$13.41
$12.93
$12.16

$11.68

Support
$10.91
$10.43
$9.66
Tweet
Growth
Description
Altimmune, Inc. is a clinical-stage immunotherapeutics company. It focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The company's proprietary platform technologies consist of RespirVec and Densigen. Altimmune Inc., formerly known as Pharmathene Inc., is based in Gaithersburg, United States.